MRD testing in early-stage breast cancer theoretically confers a significant clinical benefit with adjuvant therapy and during patient surveillance. However, there are concerns with the potential for aggressive or prolonged treatment, not to mention the specific approach to managing patients who are ctDNA positive but remain asymptomatic.
Micha et al. (Wed,) studied this question.